Novel drug delivery systems market seen reaching $187.53 billion by 2030

The novel drug delivery systems market is projected to grow from $129.45 billion in 2026 to $187.53 billion by 2030, driven by demand for targeted therapies, biologics and precision medicine. North America led in 2025, while Asia-Pacific is expected to be the fastest-growing region.

Why it matters: - Novel drug delivery systems aim to improve drug efficacy, safety and patient adherence by controlling when, where and how medicines are released in the body. - The market’s growth reflects rising demand for technologies that can support chronic disease care, oncology, biologics and targeted therapies.

What happened: - The Business Research Company released its Novel Drug Delivery Systems Global Market Report 2026 on Aug. 19, 2026. - The report values the market at $129.45 billion in 2026 and forecasts growth to $187.53 billion by 2030. - The report includes a free sample and the full market report.

The details: - The market grew from $117.66 billion in 2025 to $129.45 billion in 2026, a 10.0% compound annual growth rate. - The forecast to 2030 implies a 9.7% CAGR. - Historical growth has been driven by chronic disease prevalence, limits of traditional delivery methods, an expanding oncology and biologics pipeline, higher healthcare spending and advances in polymer and nanotechnology. - Future growth is expected to come from personalized and precision medicine, targeted cancer therapies, higher pharmaceutical R&D spending, biologics and biosimilars, and supportive regulation. - Key trends include targeted and personalized delivery platforms, lipid and polymeric nanoparticles, long-acting and controlled-release formulations, non-invasive delivery methods, and combination or hybrid delivery systems. - The report describes novel drug delivery systems as technologies designed to improve bioavailability and therapeutic outcomes by precisely controlling drug release.

Between the lines: - Neurological disorders are becoming a major demand driver because many treatments need controlled delivery across the blood-brain barrier. - Stroke highlights that need: NHS England reported 111,137 stroke admissions in England in 2023/24, including 12,533 new cases in the 50–59 age group. - The report’s regional ranking points to a mature market in North America and faster expansion in Asia-Pacific as healthcare investment and technology adoption rise. - The report also suggests buyers are looking for broader strategic tools, including TAM analysis, company scoring matrices, forecasting dashboards and market hotspot maps.

What's next: - Asia-Pacific is expected to post the fastest growth over the forecast period. - The market is likely to keep shifting toward targeted, patient-centered and non-invasive drug delivery platforms. - Continued R&D in nanoparticles, biologics and hybrid delivery systems should shape the next phase of product development.

The bottom line: - Novel drug delivery systems are moving from niche innovation to a major pharmaceutical growth market, with the strongest opportunities tied to precision medicine, oncology and neurological care.